Biotricity, Inc. - Consolidated Statements of Operations and Comprehensive Loss - USD ($)		3 Months Ended		6 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement
Revenue
Expenses:
General and administrative expenses	[1]	1,041,275	1,155,016	2,129,474	1,689,454
Research and development expenses		413,624	248,048	728,734	514,418
Total Operating Expenses		1,454,899	1,403,064	2,858,208	2,203,872
Accretion expense	[2]		473,552	879,416	594,083
Change in fair value of derivative liabilities	[3]		465,832	20,588	589,100
Net loss before income taxes		(1,454,899)	(2,342,448)	(3,758,212)	(3,387,055)
Income taxes
Net loss		(1,454,899)	(2,342,448)	(3,758,212)	(3,387,055)
Translation adjustment		(83,858)	(80,101)	(170,348)	(209,692)
Comprehensive loss		$ (1,538,757)	$ (2,422,549)	$ (3,928,560)	$ (3,596,747)
Loss per share, basic and diluted		$ (0.048)	$ (0.090)	$ (0.127)	$ (0.134)
Weighted average number of common and exercisable shares outstanding		30,590,667	25,542,107	29,529,534	25,228,725

[1] See Notes 7, 8, and 9

[2] See Note 5

[3] See Note 6